PARP1 and cancer: Poly(ADP-ribose) polymerase (PARP) enzymes are regarded as important targets for the development of anticancer drugs owing to the clinical success of PARP inhibitors Olaparib, Talazoparib, Niraparib and Rucaparib approved for cancer treatment.1